Cannabis Bioscience International Holdings (CBIH) is formally petitioning to have Ms. Alexis Bortell, long-time cannabis advocate and patient, to serve as a witness in the upcoming DEA hearing on marijuana rescheduling.
According to a press release sent today by CHIH, Alexis Bortell has been a leading voice in the fight for medical cannabis access since being diagnosed with intractable epilepsy at the age of seven.
“After enduring years of ineffective treatments with conventional anti-epileptic drugs, her remaining options were: Felbatol (Felbamate), a drug with serious and potentially life-threatening side effects, including dependency and abuse, or a lobectomy, an invasive brain surgery with the risk of devastating outcomes such as memory loss, impaired motor function, and emotional disorders”, states CBIH. “Ultimately, she found lasting relief through a combination of CBD and THC, a treatment that has kept her seizure-free for nearly a decade. Her story underscores the tragic impact of cannabis’ Schedule I classification, which perpetuates stigma that has severely limited her career opportunities in medical school due to drug tests, dictates where she must live, and creates completely unnecessary barriers to accessing her life-saving medication.”
Continue reading